CN105037195B - 乙酰谷酰胺及其注射液与制备方法 - Google Patents
乙酰谷酰胺及其注射液与制备方法 Download PDFInfo
- Publication number
- CN105037195B CN105037195B CN201510362529.2A CN201510362529A CN105037195B CN 105037195 B CN105037195 B CN 105037195B CN 201510362529 A CN201510362529 A CN 201510362529A CN 105037195 B CN105037195 B CN 105037195B
- Authority
- CN
- China
- Prior art keywords
- preparation
- aceglutamide
- injection
- sodium hydroxide
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005488 aceglutamide Drugs 0.000 title claims abstract description 73
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000003182 parenteral nutrition solution Substances 0.000 title abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000002347 injection Methods 0.000 claims abstract description 21
- 239000007924 injection Substances 0.000 claims abstract description 21
- 239000008215 water for injection Substances 0.000 claims abstract description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 88
- 239000000243 solution Substances 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 21
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 20
- 239000001632 sodium acetate Substances 0.000 claims description 20
- 235000017281 sodium acetate Nutrition 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- 238000007689 inspection Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 5
- 239000003610 charcoal Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 abstract description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 239000013078 crystal Substances 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000036632 reaction speed Effects 0.000 abstract description 3
- 238000001179 sorption measurement Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- -1 acetyl compound Chemical class 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000003002 pH adjusting agent Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000011835 investigation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910017488 Cu K Inorganic materials 0.000 description 3
- 229910017541 Cu-K Inorganic materials 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000005260 alpha ray Effects 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000005261 decarburization Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510362529.2A CN105037195B (zh) | 2015-06-26 | 2015-06-26 | 乙酰谷酰胺及其注射液与制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510362529.2A CN105037195B (zh) | 2015-06-26 | 2015-06-26 | 乙酰谷酰胺及其注射液与制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105037195A CN105037195A (zh) | 2015-11-11 |
CN105037195B true CN105037195B (zh) | 2018-04-13 |
Family
ID=54444241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510362529.2A Active CN105037195B (zh) | 2015-06-26 | 2015-06-26 | 乙酰谷酰胺及其注射液与制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105037195B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107582521A (zh) * | 2017-09-27 | 2018-01-16 | 江西省子轩科技有限公司 | 一种稳定性好的乙酰谷酰胺注射液及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102018668A (zh) * | 2010-12-08 | 2011-04-20 | 上海朝晖药业有限公司 | 一种乙酰谷酰胺注射液的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101434559B (zh) * | 2008-12-12 | 2012-01-04 | 上海朝晖药业有限公司 | 乙酰谷酰胺的制备方法 |
CN102276496B (zh) * | 2011-07-28 | 2012-07-04 | 周晓东 | 乙酰谷酰胺化合物及其药物组合物 |
CN102358721B (zh) * | 2011-08-26 | 2013-08-07 | 贺金凤 | 一种更为稳定的乙酰谷酰胺化合物及其药物组合物 |
CN103012192B (zh) * | 2013-01-10 | 2014-08-20 | 黄明芳 | 一种新型乙酰谷酰胺化合物及其药物组合物 |
CN104140378A (zh) * | 2014-05-22 | 2014-11-12 | 浙江磐谷药源有限公司 | 乙酰谷酰胺特种超细粉体冻干制剂及其制备方法 |
-
2015
- 2015-06-26 CN CN201510362529.2A patent/CN105037195B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102018668A (zh) * | 2010-12-08 | 2011-04-20 | 上海朝晖药业有限公司 | 一种乙酰谷酰胺注射液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105037195A (zh) | 2015-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104892612B (zh) | 一种艾德力布的无定型物及其制备方法 | |
CN110507616A (zh) | 一种盐酸金霉素可溶性粉及其制备方法 | |
CN102140079B (zh) | 新乌碱及其制备方法和以该化合物为活性成分的药物组合物及用途 | |
CN105037195B (zh) | 乙酰谷酰胺及其注射液与制备方法 | |
CN110215433A (zh) | 一种氯前列醇注射液及其制备方法 | |
CN109820827A (zh) | 一种注射用阿扎胞苷冻干粉针及其制备方法 | |
CN103191051B (zh) | 一种奈拉滨注射液组合物及其制备方法 | |
CN107595769A (zh) | 一种磺达肝癸钠注射液组合物的制备方法 | |
CN102258507B (zh) | 含有布洛芬的药物组合物 | |
CN102846561A (zh) | 一种供注射用的奥扎格雷钠药物组合物 | |
CN109620804B (zh) | 一种注射用头孢曲松钠粉针制剂及其制备方法 | |
CN105640935A (zh) | 供注射用甲磺酸艾日布林药物组合物 | |
CN105476954B (zh) | 一种盐酸洛美沙星注射剂及制备方法 | |
CN106432277A (zh) | 采用强场耦合结晶技术制备的头孢哌酮钠化合物和舒巴坦钠化合物以及制成的组合物 | |
CN103027890B (zh) | 供注射用的布洛芬药物组合物 | |
CN110327371A (zh) | 碳酸氢钠林格注射液及其制备方法 | |
CN103483262A (zh) | 稳定的依达拉奉三水化合物及其药物组合物 | |
CN106188177A (zh) | 一种阿奇霉素化合物的制备方法及其药物制剂 | |
CN103751104A (zh) | 依达拉奉注射液及其制备方法 | |
CN103655533A (zh) | 一种供注射用的门冬氨酸鸟氨酸药物组合物 | |
CN103110624A (zh) | 一种阿莫西林钠与克拉维酸钾的药物组合物 | |
CN107157926A (zh) | 一种多西他赛注射剂的制备方法 | |
CN107793472A (zh) | 奥利万星二磷酸盐的晶型及其制备方法和用途 | |
CN103705933A (zh) | 奥卡西平药物组合物及制备方法 | |
CN107582521A (zh) | 一种稳定性好的乙酰谷酰胺注射液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acetylglutamine and its injection and preparation method Effective date of registration: 20210730 Granted publication date: 20180413 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211014 Granted publication date: 20180413 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No.8 Kangpu Avenue, high tech Industrial Park, Hanshou County, Changde City, Hunan Province, 415900 Patentee after: KAMP PHARMACEUTICALS Co.,Ltd. Address before: 12 / F, building B, Lugu information port, 658 Lugu Avenue, high tech Zone, Changsha City, Hunan Province, 410205 Patentee before: KAMP PHARMACEUTICALS Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acetylglutamine and its injection and preparation method Effective date of registration: 20211028 Granted publication date: 20180413 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021980011259 |